Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
Budget 2023
Budget 2023

Sun Pharma Q3 Preview: Consolidated PAT to gain 10% YoY while revenue to rise 11%

Net sales for the quarter likely to rise 11.5 percent year-on-year growth to Rs 9853 crore for the December quarter

January 30, 2022 / 08:31 PM IST
Analysts are positive on the growth prospect of Sun Pharma's speciality portfolio aided by Winlevi launch despite sectoral headwinds in key markets.

Analysts are positive on the growth prospect of Sun Pharma's speciality portfolio aided by Winlevi launch despite sectoral headwinds in key markets.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharmaceuticals Industries Ltd is expected to report a 10 percent year- on-year increase in consolidated net profit to Rs 1,957 crore for the quarter ended December 2021, according to an average of estimates from five brokerages polled by Moneycontrol.

Net sales for the quarter likely to rise 11.5 percent year-on-year growth to Rs 9,853 crore for the December quarter, the poll showed.

Taro's sales are expected to grow 6.8% YoY to Rs 1103.6 crores while US (ex-Taro) is likely to grow 4.2% YoY to Rs 1,799.9 crore.  EBITDA margins are expected to decline 73 basis points to 26.5%  due to higher input cost pressures, R&D ramp up and Winlevi cost.